검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | taxane drug |
Overview Company | Chipscreen Biosciences, Ltd. |
Overview Modality | ADC |
Overview Target | HER2 |
Overview Indication | HER2-positive Metastatic Breast Cancer; First-line Treatment |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
MoA Mechanism | target engagement, evidenced by decreased percent androgen receptor |
MoA Biomarker | biomarker of CIPN |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Gut microbiota and metabolite disruption during breast cancer chemotherapy is associated with peripheral neuropathy sensory symptoms and pain.. Chemotherapy-induced peripheral neuropathy (CIPN) is a common and serious adverse effect of chemotherapeutic agents such as taxanes, platinum compounds, and vinca alkaloids. Efforts to prevent and treat CIPN are impeded by an incomplete understanding of it… |
Clinical Primary efficacy | ORR 81.1% |
Clinical ORR | 81.1% |
Clinical Result source | ClinicalTrials.gov NCT00455533 |
Clinical Data Tier / Score | A · 69 |
Clinical Program phase | PHASE_3 |
Clinical Clinical sync | 2026년 7월 18일 (8일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | taxane drug |
Overview Company | Chipscreen Biosciences, Ltd. |
Overview Modality | ADC |
Overview Target | HER2 |
Overview Indication | HER2-positive Metastatic Breast Cancer; First-line Treatment |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
MoA Mechanism | target engagement, evidenced by decreased percent androgen receptor |
MoA Biomarker | biomarker of CIPN |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Gut microbiota and metabolite disruption during breast cancer chemotherapy is associated with peripheral neuropathy sensory symptoms and pain.. Chemotherapy-induced peripheral neuropathy (CIPN) is a common and serious adverse effect of chemotherapeutic agents such as taxanes, platinum compounds, and vinca alkaloids. Efforts to prevent and treat CIPN are impeded by an incomplete understanding of it… |
Clinical Primary efficacy | ORR 81.1% |
Clinical ORR | 81.1% |
Clinical Result source | ClinicalTrials.gov NCT00455533 |
Clinical Data Tier / Score | A · 69 |
Clinical Program phase | PHASE_3 |
Clinical Clinical sync | 2026년 7월 18일 (8일 전) |
추천 비교
추천 비교